Cargando…

Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell‐derived neural crest cells

Mesenchymal stem cell‐ or osteoblast‐derived osteosarcoma is the most common malignant bone tumor. Its highly metastatic malignant phenotypes, which are often associated with a poor prognosis, have been correlated with the modulation of TP53‐ and cell‐cycle‐related pathways. MYC, which regulates the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukae, Kyosuke, Takenobu, Hisanori, Endo, Yuki, Haruta, Masayuki, Shi, Tianyuan, Satoh, Shunpei, Ohira, Miki, Funato, Michinori, Toguchida, Junya, Osafune, Kenji, Nakahata, Tatsutoshi, Kanda, Hiroaki, Kamijo, Takehiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154822/ https://www.ncbi.nlm.nih.gov/pubmed/36661413 http://dx.doi.org/10.1111/cas.15730

Ejemplares similares

Polycomb EZH1 regulates cell cycle/5‐fluorouracil sensitivity of neuroblastoma cells in concert with MYCN
por: Shinno, Yoshitaka, et al.
Publicado: (2022)

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
por: Parvin, Sultana, et al.
Publicado: (2023)

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma
por: Akter, Jesmin, et al.
Publicado: (2021)

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications
por: Li, Zhenghao, et al.
Publicado: (2018)

CFC1 is a cancer stemness-regulating factor in neuroblastoma
por: Chikaraishi, Koji, et al.
Publicado: (2017)

MYCN induces neuroblastoma in primary neural crest cells
por: Olsen, R R, et al.
Publicado: (2017)

Development of RNA/DNA automated extraction and purification device for infectious disease diagnosis
por: Mukae, Kyosuke, et al.
Publicado: (2023)

DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells
por: Ando, Kiyohiro, et al.
Publicado: (2023)

FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis
por: Ando, Kiyohiro, et al.
Publicado: (2021)

Derivation of Mesenchymal Stromal Cells from Pluripotent Stem Cells through a Neural Crest Lineage using Small Molecule Compounds with Defined Media
por: Fukuta, Makoto, et al.
Publicado: (2014)

MycN Is Critical for the Maintenance of Human Embryonic Stem Cell-Derived Neural Crest Stem Cells
por: Zhang, Jie Ting, et al.
Publicado: (2016)

CBMS-10 FUNCTIONAL ROLE OF MYCN IN SHH TYPE TP53 MUTATED MB’S METABOLISM
por: Yokogami, Kiyotaka, et al.
Publicado: (2019)

Correction: MycN Is Critical for the Maintenance of Human Embryonic Stem Cell-Derived Neural Crest Stem Cells
por: Zhang, Jie Ting, et al.
Publicado: (2016)

MBRS-21. CLINICAL AGGRESSIVENESS OF TP53-WILD TYPE SONIC HEDGEHOG MEDULLOBLASTOMA WITH MYCN AMPLIFICATION
por: Mitani, Yuichi, et al.
Publicado: (2020)

Myelin protein zero (P0)- and Wnt1-Cre marked muscle resident neural crest-derived mesenchymal progenitor cells give rise to heterotopic ossification in mouse models
por: Zhao, Chengzhu, et al.
Publicado: (2022)

Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2023)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation
por: Newman, Erika A., et al.
Publicado: (2017)

Induction of Neural Crest Stem Cells From Bardet–Biedl Syndrome Patient Derived hiPSCs
por: Barrell, William B., et al.
Publicado: (2019)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Phenotypic differences of patients with fibrodysplasia ossificans progressive due to p.Arg258Ser variants of ACVR1
por: Nakahara, Yasuo, et al.
Publicado: (2015)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

Comparative epigenomics by machine learning approach for neuroblastoma
por: Sugino, Ryuichi P., et al.
Publicado: (2022)

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas
por: Kaneko, Yoshiki, et al.
Publicado: (2015)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas
por: Suenaga, Yusuke, et al.
Publicado: (2014)

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
por: Hasan, Md. Kamrul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e3ra2rcaatqm3higlqcqlk7vs7